期刊文献+

右雷佐生的合成 被引量:1

Synthesis of Dexrazoxane
暂未订购
导出
摘要 以(±)-1,2-丙二胺为起始原料,D-(-)-酒石酸为拆分剂,经拆分得(S)-1,2-丙二胺二酒石酸盐;再与氯化钾反应得(S)-1,2-丙二胺二盐酸盐;然后在氢氧化钠催化下与氯乙酸缩合制备(S)-N,N,N',N'-1,2-丙二胺四乙酸;最后与甲酰胺环合制得心脏保护剂右雷佐生。总收率为35.7%,其结构经1H NMR和IR确证。 Dexrazoxane,a cardiac medicine,was synthesized in 35.7% overall yield starting from racemic 1,2-diaminopropane.The resolution of 1,2-diaminopropane with D-(-)-tartaric acid followed by reaction with potassium chloride resulted in(S)-1,2-diaminopropane dihydrochloride,which was further converted into the title compound in two steps.The structure was confirmed with 1H NMR and IR.
出处 《精细化工中间体》 CAS 2010年第4期38-40,共3页 Fine Chemical Intermediates
关键词 右雷佐生 S-1 2-丙二胺 拆分 合成 dexrazoxane S-1 2-diaminopropane resolution synthesis
  • 相关文献

参考文献8

  • 1蒋莎义,孙迎红,李学琴,马沛然.右雷佐生对心肌保护作用研究进展[J].实用儿科临床杂志,2004,19(11):993-994. 被引量:3
  • 2Wiseman L R, Spencer C M. Dexrazoxane: A review of its as a cardioproteetive agent in patients [J]. Anthracycline-base Chemotherapy Drugs, 1998, 56(3): 385- 403.
  • 3Hochster H, Wasserheit C, Speyer J. Cardiotoxicity and cardioprotection during chemotherapy [J]. Curr Opin Oncol, 1995, 7: 304-309.
  • 4郭德嵩,胡文.右雷佐生预防蒽环类药物诱发心脏毒性的临床研究与作用机制[J].国外医学(药学分册),2000,27(6):335-339. 被引量:8
  • 5王玉玲,宋宏锐,宋爱华.丙二胺的拆分及右雷佐生的合成[J].中国药物化学杂志,2003,13(2):106-107. 被引量:5
  • 6Francis P, Dwyer, Francis L, et al. Preparation of 1,2- Propylenediaminetetra acetic acie [J]. Inorgain Chemistry, 1959, 81 (10); 2 955-2 956.
  • 7Duane D, Miller, Fu-Lian H, et al. Stereochemical studies of adrenergic drugs.optically active derivatives of imidazolines[J]. Journal of Medicinal Chemistry, 1976, 19 (12): 1 383.
  • 8Creighton A M.National research development corporation: US, 3941790A[P]. 1976-03-02.

二级参考文献15

  • 1全国原料药生产工艺汇编编写组.全国原料药生产工艺汇编[M].北京:国家医药管理总局,1980.405.
  • 2Zucchi R, Danesi R. Cardiac toxicity of antineoplastic anthracyclines [J].Curr Med Chem Anti Cancer Agents, 2003,3(2): 151 - 171.
  • 3Iarussi D, Indolfi P, Casale F, et al. Recent advances in the prevention of anthracycline cardiotoxicity in childhood [ J ]. Curr Med Chem,2001,8(13): 1649 - 1660.
  • 4Schroeder PE, Hasinoff BB. The doxorubicin-cardioprotective drug dexrazoxane undergoes metabolism in the rat to its metal ion-chelating form ADR-925 [J]. Cancer Chemother Pharmacol , 2002, 50(6): 509 - 513.
  • 5Beer EL, Bottone AE, Rijk MC, et al. Dexrazoxane pre-treatment protects skinned rat cardiac trabeculae against delayed doxorubicininduced impairment of crossbridge kinetics [J]. Br J Pharmacol,2002,135(7): 1707 - 1714.
  • 6Herman EH,Zhang J,Rifai N,et al. The use of serum levels of cardiac troponin T to compare the protective activity of dexrazoxane against doxorubicin and mitoxantrone-induced cardiotoxicity[J]. Cancer Chemother Pharmacol ,2001,48(4) :297 - 304.
  • 7Swain SM, Whaley FS, Gerber MC, et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer[J]. J Clin Oncol, 1997,15(4): 1318 - 1332.
  • 8Swain SM,Whaley FS,Gerber MC, et al. Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy[J]. J Clin Oncol, 1997,15(4): 1333 - 1340.
  • 9Langer SW,Sehested M,Jensen PB, et al. Dexrazoxane is a potent and specific inhibitor ofanthracycline induced subcutaneous lesions in mice[J]. Ann Oncol,2001,12(3) :405 - 410.
  • 10Styczynski J, Wysocki M, Balwierz W, et al. Dexrazoxane has no impact on sensitivity of childhood leukemic blasts to daunorubicin[J].Leukemia, 2002,16 (5): 820 - 825.

共引文献12

同被引文献2

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部